These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3667167

  • 1. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S, Gasparini G, Veronesi A, Tirelli U, Pacciarini MA, Crivellari D, Zagonel V, Monfardini S.
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP, Blessing JA, Yordan E, Beecham J.
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP, Blessing JA, Berman ML.
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP.
    Cancer; 1992 Sep 15; 70(6):1591-7. PubMed ID: 1516010
    [Abstract] [Full Text] [Related]

  • 5. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
    Alberts DS, Mason-Liddil N, Stock-Novack D, O'Toole RV, Abbott TM, Salmon SE.
    Am J Clin Oncol; 1992 Apr 15; 15(2):146-9. PubMed ID: 1553903
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
    De Mulder PH, Cappelaere P, Cognetti F, Verweij J, Schornagel JH, Vermorken JB, Kirkpatrick A, Lefebvre JL.
    Cancer Chemother Pharmacol; 1994 Apr 15; 33(5):438-40. PubMed ID: 8306420
    [Abstract] [Full Text] [Related]

  • 7. Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.
    Shin DM, Kramer AM, Dimery IW, Raber MN, Ewer M, Hong WK.
    Invest New Drugs; 1991 Feb 15; 9(1):89-91. PubMed ID: 2026488
    [Abstract] [Full Text] [Related]

  • 8. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB, Van Echo D, Korzun AH, Henderson IC, Campbell T, Vogelzang NJ, Rice MA, Wood W.
    Am J Clin Oncol; 1990 Jun 15; 13(3):233-7. PubMed ID: 2346128
    [Abstract] [Full Text] [Related]

  • 9. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
    Hochster H, Hunt M, Green M, Parkinson D, Smith T.
    Invest New Drugs; 1990 Aug 15; 8(3):329-32. PubMed ID: 2272773
    [Abstract] [Full Text] [Related]

  • 10. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M.
    Invest New Drugs; 1990 May 15; 8(2):221-6. PubMed ID: 2166722
    [Abstract] [Full Text] [Related]

  • 11. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB, Salmon SE, Fleming TR.
    Invest New Drugs; 1990 Feb 15; 8(1):81-5. PubMed ID: 2188929
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
    Rozencweig M, Crespeigne N, Kenis Y.
    Invest New Drugs; 1983 Feb 15; 1(4):309-13. PubMed ID: 6678877
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
    Planting AS, de Mulder PH, de Graeff A, Verweij J.
    Eur J Cancer; 1997 Jan 15; 33(1):61-5. PubMed ID: 9071901
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of 4'-deoxydoxorubicin given weekly.
    Sessa C, Bosia L, Kaplan S, Pusterla C, Varini M, Cavalli F.
    Invest New Drugs; 1984 Jan 15; 2(4):369-73. PubMed ID: 6511241
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW.
    Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121
    [Abstract] [Full Text] [Related]

  • 16. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
    Green JB, Green S, O'Toole RV, Alberts DS, Nahhas WA, Wallace DL.
    Invest New Drugs; 1991 May 15; 9(2):191-3. PubMed ID: 1874602
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.
    Somlo G, Doroshow J, Akman S, Leong L, Margolin K, McNamara M, Multhauf P, Blayney D, Morgan R, Raschko J.
    Invest New Drugs; 1991 Feb 15; 9(1):83-5. PubMed ID: 2026486
    [Abstract] [Full Text] [Related]

  • 18. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.
    Kish JA, Al-Sarraf M.
    Am J Clin Oncol; 1984 Oct 15; 7(5):535-7. PubMed ID: 6507374
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
    Rigas JR, Kris MG, Gralla RJ, Heelan RT, Marks LD.
    Invest New Drugs; 1991 May 15; 9(2):187-90. PubMed ID: 1651908
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of mitoxantrone in head and neck carcinoma.
    Sridhar KS, Hussein AM, Benedetto P, Waldman SM, Feun LG, Savaraj N, Richman SP, Ardalan B, Desai P.
    Am J Clin Oncol; 1991 Aug 15; 14(4):298-304. PubMed ID: 1650529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.